"Klotho peptide" almost always refers to a Klotho-derived peptide - a short fragment of the anti-aging Klotho protein, not the full protein. The two most studied are KP1 (a 30-amino-acid fragment, residues 56-87) and KP6. KP1 blocks TGF-β signaling and reduced kidney fibrosis and cellular senescence in 2022-2024 preclinical studies; KP6 inhibits Wnt/β-catenin signaling in diabetic-kidney models. There is no approved drug and no human dosing protocol - these are laboratory research reagents, sold by scientific supply houses at roughly $185-965 per milligram.
Research notes
What "Klotho peptide" actually means
Search "klotho peptide" and most results are not about the famous longevity protein directly - they are about Klotho-derived peptides, short synthetic fragments engineered to keep one useful activity of the full protein in a deliverable size. The full-length Klotho protein (~130 kDa) has the strongest longevity evidence of almost any aging target, but it is too large for practical drug delivery. The peptides are the workaround.
Two fragments dominate the research literature:
- KP1 (Klotho-derived peptide 1) - a 30-amino-acid fragment corresponding to residues 56-87 of human Klotho. It binds TGF-β receptor 2 and blocks TGF-β signaling. In a 2022 Nature Communications study it reduced kidney fibrosis; a 2024 study reported it inhibiting cellular senescence by restoring endogenous Klotho expression.
- KP6 (Klotho-derived peptide 6) - a Wnt/β-catenin signaling inhibitor that sequesters Wnt ligands and reduced injury in diabetic-kidney-disease models.
So when a longevity forum, a supply catalog, or an AI answer says "klotho peptide," it almost always means KP1 or KP6, not the whole protein.
What Klotho peptides do
The mechanism is targeted, not systemic "anti-aging." KP1's job is to interrupt TGF-β signaling, the pathway that drives tissue fibrosis. By binding TGF-β receptor 2, KP1 reduced scarring and preserved organ function in preclinical kidney models, and a 2026 study extended the finding to a fibrosis model of erectile function. KP6 works one pathway over, inhibiting Wnt/β-catenin signaling to cut injury markers in diabetic kidney disease.
The through-line is anti-fibrotic and anti-senescence activity in animal and in-vitro models. None of this has cleared human clinical trials, and neither peptide is an approved drug.
Why the underlying Klotho biology is unusually strong
The peptides are interesting because the protein behind them is. Klotho has three converging lines of evidence that most early-stage longevity targets lack.
Mouse lifespan extension. Klotho overexpression extends mouse lifespan 20-30% in both sexes, replicated across labs. Knockout phenotype. Klotho-deficient mice develop a syndrome meeting formal criteria for accelerated aging - vascular calcification, osteoporosis, cognitive decline, shortened lifespan. Human cohort correlation. Higher serum Klotho correlates with longer lifespan, better cognitive performance, and lower cardiovascular mortality across cohorts including InCHIANTI.
The gene was named in 1997 after the Greek goddess Klotho, who spins the thread of life, because deleting it in mice so closely mimicked aging. The open question has always been delivery - which is exactly the gap the KP1/KP6 peptides try to close.
Can you buy Klotho peptide, and where?
Yes, but know what you are buying. Authentic Klotho-derived peptides are sold as laboratory research reagents, not consumer products:
| Source | Product | Approx. price (checked July 2026) |
|---|---|---|
| AMSBio | Klotho-derived peptide 1 (56-87), 1 mg | ~$185 |
| Tocris / R&D Systems | Klotho-derived peptide 1 and 6 | research-catalog pricing |
| TargetMol | Klotho-derived peptide 1 (56-87) TFA | ~$965 |
| Thermo Fisher | Human Klotho synthetic peptide (PEP-1192) | research-catalog pricing |
| BioLongevity Labs | Recombinant full-length α-Klotho (alphaKlothoLR), 20 mcg | longevity-vendor pricing |
Two cautions. First, skincare "Klotho peptide" serums sold on general retail sites are cosmetic products using the name loosely - they are not KP1/KP6 and carry none of the research data above. Second, if a research-peptide vendor lists a "Klotho peptide" without specifying KP1, KP6, or a recombinant full-length product with a molecular weight and a third-party COA, treat the listing as unverified. Run any COA through our COA verifier before trusting a purity claim.
What this means for buyers
Klotho is at an earlier stage than rapamycin or NAD+: real, published peptide candidates (KP1, KP6) with preclinical anti-fibrotic and anti-senescence data, but no human trials, no approved drug, and no established human dose. All products are sold research-use only. A buyer wanting an immediately-administrable Klotho therapy does not have one yet; a buyer tracking Klotho as a longevity biomarker can request a serum Klotho test through a longevity-medicine clinician.
Related reading
- Rapamycin peptide page - the most-deliverable longevity intervention with mouse-replicated lifespan data.
- NAD+ peptide page - the other major aging-mechanism target with clinical-research interest.
- Epitalon peptide page - earlier-stage longevity peptide with a different evidence base.
- KLOW stack research read - where Klotho fits alongside other longevity peptides in a stack context.
- Longevity peptides 2026 overview - the broader longevity-compound landscape.
What it's researched for
- longevity research
- kidney fibrosis / anti-senescence research
- cognitive / neuroprotective research
Where to source it
ALL 0 VENDORS →No vendors in our audit cycle currently list Klotho as a specialty. Cross-reference the leaderboard for vendors that may stock it on request.
Frequently asked about Klotho
What is a Klotho peptide?
A Klotho peptide is a short fragment derived from the Klotho anti-aging protein that reproduces part of its activity without the delivery problems of the large full-length protein. The best-characterised are KP1 (residues 56-87, a 30-amino-acid peptide) and KP6. They are research reagents, not approved drugs.
What is Klotho peptide used for?
In preclinical research, Klotho-derived peptides are used to study kidney fibrosis, diabetic kidney disease, and cellular senescence. KP1 blocks TGF-β signaling by binding TGF-β receptor 2; KP6 inhibits Wnt/β-catenin signaling. A 2026 study also reported KP1 limiting fibrosis in an erectile function model. All uses are laboratory-stage, not clinical.
Where can I buy Klotho peptides?
Authentic Klotho-derived peptides (KP1, KP6) are sold as research reagents by scientific supply houses - Tocris, R&D Systems, AMSBio, TargetMol, Thermo Fisher - typically $185 to $965 per milligram. Recombinant full-length Klotho is sold by longevity-focused vendors such as BioLongevity Labs. Skincare "Klotho peptide" serums on retail sites are unrelated cosmetic products, not KP1/KP6.
What is the difference between Klotho protein and a Klotho-derived peptide?
The Klotho protein is the full ~130 kDa molecule your body makes; it has the strongest longevity evidence but is too large for practical drug delivery. A Klotho-derived peptide (KP1, KP6) is a short synthetic fragment engineered to keep one specific activity - TGF-β or Wnt inhibition - in a deliverable size. The peptides are what most "klotho peptide" searches and products refer to.
What is the Klotho peptide dosage?
There is no established human dosage; Klotho peptides are preclinical. In rodent studies KP1 was dosed around 1 mg/kg/day for about four weeks. Full-length Klotho is studied at 10-50 mcg/kg in mice. Anyone selling a "Klotho peptide" with a human dosing chart is going beyond the published evidence.
Does Klotho really work?
The biology is unusually strong: klotho-overexpressing mice live 20-30% longer, knockout mice age prematurely, and higher human Klotho levels correlate with longer lifespan and better cognition. The Klotho-derived peptides show clear preclinical effects on fibrosis and senescence. What is missing is human clinical proof and an approved product - the gap between "works in models" and "works in people" is still open.